Which Market Should You Register First? Where to place a pharmaceutical product first is no longer only about focusing on the world’s biggest market. The initial regulatory filing may influence subsequent approvals price as well as reimbursement, access for patients potential, reliance, evidence preparation and timing of commercial activities. Pharmaceutical launch sequencing is therefore to be considered an inter-functional decision that connects regulatory strategies with access to markets, pricing, commercial readiness and supply.
Which Market Should You Register First?
For many innovative medicines, the United States remains an attractive early market because of its commercial scale and established regulatory environment. But the largest market is not automatically the best first market.
- Another jurisdiction may offer greater strategic value through:
- Faster or more suitable regulatory pathways
- Significant unmet patient need
- Stronger reimbursement potential
- Reference-authority value
- Regulatory reliance opportunities
- Greater evidence readiness
- Better operational or supply readiness
- Lower competitive pressure
The strongest first market is the one that creates the greatest value across the product’s global lifecycle, not simply the market with the highest theoretical revenue opportunity.
What is Pharmaceutical Launch Sequencing?
Pharmaceutical launch sequencing is the strategic process of deciding when and in what order a medicine should be submitted, approved, priced, reimbursed and commercially introduced across markets.
Three related sequences need to be distinguished:
- Registration sequence: the order in which regulatory applications are submitted.
- Approval sequence: the order in which regulatory authorities grant marketing authorisation.
- Commercial launch sequence: the order in which the medicine becomes commercially available to patients.
These timelines can differ significantly.
A medicine may receive regulatory approval while pricing, reimbursement, HTA, manufacturing or operational requirements are still unresolved.
Regulatory approval does not automatically mean effective market access.
Why Does the First Registration Market Matter?
Regulatory precedent
An assessment from a trusted regulatory authority may support later filings in jurisdictions using reliance, recognition or abridged assessment mechanisms.
WHO supports regulatory reliance to make better use of the work and expertise of other regulators while the relying authority remains responsible for its own regulatory decision.
This means the strategic value of the first approval may extend well beyond the first market itself.
Evidence learning
The first major submission tests the strength of the core dossier and benefit-risk narrative.
Regulatory assessment may uncover:
- CMC concerns
- Safety questions
- Labelling gaps
- Statistical limitations
- Population-specific issues
- Other evidence gaps
Addressing these points early can strengthen subsequent submissions and reduce avoidable duplication.
Pricing implications
Prices established in one country may affect pricing or reimbursement discussions in markets using external or international reference pricing.
Launch order should therefore be modelled alongside global pricing strategy rather than decided market by market.
Organisational learning
Early markets can also reveal practical issues around physician adoption, patient access, payer objections, supply, medical education and commercial execution.
Those lessons can improve subsequent launch waves.
What Factors Determine Pharmaceutical Launch Sequence?
A robust pharmaceutical registration strategy should evaluate markets across several dimensions.
1. Regulatory Feasibility
Does the available clinical, nonclinical and CMC package meet the target authority’s requirements? Could an accelerated or priority pathway apply?
2. Reference and Reliance Value
Could approval from this regulator support reliance, recognition or abridged assessment in later markets?
3. Patient Need
Is there significant unmet medical need or a patient population that could benefit from earlier access?
4. Market Opportunity
Consider eligible patients, diagnosis rates, treatment patterns, competition and realistic uptake.
5. Pricing Potential
Assess achievable pricing, reimbursement conditions and potential international reference-pricing exposure.
6. HTA and Reimbursement
How long after approval could patients realistically gain access? What comparative evidence will HTA bodies and payers require?
7. Evidence Readiness
Different regulators and HTA bodies may expect different comparators, endpoints, populations or supporting analyses.
8. Intellectual Property
Remaining patent life, regulatory exclusivity and expected generic or biosimilar competition can materially affect the commercial window.
9. Manufacturing and Supply Readiness
Manufacturing capacity, packaging, local labelling, import requirements and distribution must be able to support the intended launch.
A market should move early when regulatory attractiveness and practical launch readiness align.
Why is Pharmaceutical Launch Sequencing Changing in 2026?
Historically, many innovative medicines followed a broadly recognisable sequence:
United States → Major European Markets → Japan → Other Developed Markets → Selected Emerging Markets
Parallel eCTD submissions, regulatory reliance, collaborative review and market-specific launch waves are making global launch strategies more interconnected.
U.S. Pricing Relationships are More Strategic
Current U.S. Most-Favored-Nation (MFN) pricing initiatives have increased the strategic importance of international pricing relationships for affected pharmaceutical manufacturers.
As of May 2026, the U.S. administration reported voluntary MFN pricing agreements with 17 major pharmaceutical manufacturers and stated that it was pursuing legislation to codify the framework. This does not mean that lower-priced markets should automatically be delayed. It means global launch teams should model potential international pricing interdependencies before confirming launch order.
EU HTA Requires Earlier Evidence Alignment
From 12 January 2025, new cancer medicines and advanced therapy medicinal products became subject to Joint Clinical Assessment (JCA) under the EU Health Technology Assessment framework.
JCA provides a common scientific assessment of the relative clinical effects of a health technology and supports national HTA processes. It does not replace country-level pricing and reimbursement decisions. Companies therefore increasingly need to align as per this earlier in development:
EMA Evidence Strategy + JCA Requirements + National HTA Planning + Country Launch Preparation
Regulatory Reliance is Turning Sequencing into a Network Strategy
Reliance changes the strategic question from:
“Which country comes next?”
to:
“Which approval can support the next group of markets?”
A moderate-sized market may create greater global value than a larger standalone market if its regulator is accepted as a reference authority by several later-wave jurisdictions.
Companies should therefore map:
Reference Authority → Reliance Markets → Eligibility → Required Documents → Expected Review Benefit
before finalising the global sequence.
A Simple Pharmaceutical Launch Sequencing Example
Consider two hypothetical markets.
Market A offers substantial standalone commercial value but has limited influence on subsequent regulatory filings.
Market B offers moderate commercial value, but its regulator can serve as a relevant reference authority for three priority markets that the company wants to enter next.
If approval in Market B can materially support those downstream registrations, Market B may create greater total lifecycle value, despite being commercially smaller.
That is the principle behind modern pharmaceutical launch sequencing:
Optimise the global pathway, not just the first country.
Therapeutic Area Can Change the Optimal Launch Sequence
Therapeutic Area Can Change the Optimal Launch Sequence
Oncology
Eligible oncology products may benefit from coordinated international regulatory strategies. FDA’s Project Orbis provides a framework for concurrent submission and review of oncology products among participating international regulators. It supports regulatory collaboration but does not mean every participating authority will necessarily approve a product at the same time.
Rare Diseases
Diagnosed patient numbers, centres of excellence, specialist access, orphan incentives and reimbursement willingness may matter more than total market population.
ATMPs and Cell and Gene Therapies
Approval alone does not establish launch readiness.
Treatment-centre qualification, manufacturing capacity, cold-chain logistics, chain of identity or custody, long-term follow-up and reimbursement can determine whether an early launch is operationally realistic.
Primary-Care Medicines
Payer coverage, prescriber access, formulary position, competitive intensity and commercial scale may have greater influence.
The optimal sequence should reflect the product’s regulatory, clinical, commercial and operational profile.
How to Build a Global Pharmaceutical Registration Sequence
A strong sequencing process should begin before the first major marketing-authorisation application.
Step 1: Define the Target Product Profile
Clarify the indication, target population, clinical evidence, differentiation, safety profile, manufacturing needs and expected value proposition.
Step 2: Map the Regulatory Landscape
Assess regulatory pathways, review timelines, accelerated options, local data expectations, GMP requirements and reliance eligibility.
Step 3: Map Market Access
Evaluate HTA requirements, pricing, reimbursement, evidence expectations and expected access delays.
Step 4: Model Pricing Interdependencies
Identify markets using external reference pricing and assess how different launch prices and dates could influence subsequent markets.
Step 5: Assess Commercial Opportunity
Take into consideration potential patients who are eligible, diagnostic rate, competition, anticipated rate of uptake, and realistic revenue potential.
Step 6: Assess Operational Readiness
Review packaging, manufacturing distribution, local labelling pharmaceutical safety, representation of the regulatory and commercial ready.
Step 7: Identify Reliance Opportunities
Find out if one approval can help speed up or improve efficiency of review elsewhere.
Step 8: Build Launch Waves
Instead of using a fixed ladder of countries, markets can be classified into:
Wave 1: High-value and strategic reference markets
Wave 2: Major reliance and high-priority markets
Wave 3: Broader expansion markets
Wave 4: Opportunistic or infrastructure-dependent markets
Parallel submissions may be appropriate within a wave when evidence, resources and local regulatory requirements allow.
Common Pharmaceutical Launch Sequencing Mistakes
Some of the most damaging mistakes are strategic rather than procedural:
- Treating approval as equivalent to patient access
- Selecting markets purely by commercial size
- Ignoring international pricing interactions
- Starting HTA planning too late
- Applying the same launch sequence to every therapeutic area
- Overlooking manufacturing and supply constraints
- Ignoring patent and exclusivity timing
- Treating emerging markets as one homogeneous group
- Filing sequentially when reliance or parallelisation is possible
- Optimising the first launch instead of the global lifecycle
The highest-value first market does not necessarily create the highest-value global launch sequence.
Conclusion
Pharmaceutical launch sequencing is no longer about selecting the largest market first and following a predetermined country list.
A strong global pharmaceutical launch strategy identifies which markets should move first, which can move in parallel, which approvals can support subsequent registrations and how every regulatory and commercial decision affects the medicine’s global lifecycle.
Frequently Asked Questions
There is no universally correct first market. The decision should balance regulatory feasibility, patient need, reference-authority value, pricing, reimbursement, evidence readiness, intellectual property, supply and commercial opportunity.
No. A smaller reference market may create greater strategic value if its approval supports subsequent registrations or allows patients to gain meaningful access sooner.
Yes, when the development package, resources and local regulatory requirements permit. Reliance, work-sharing and collaborative review may also support parallel or near-parallel submissions.
Reliance allows a regulator to take account of regulatory work performed by another trusted authority while retaining responsibility for its own decision. A strategically selected reference approval can therefore support more efficient expansion into later markets.
Regulatory approval does not guarantee reimbursement or immediate patient access. HTA evidence requirements and reimbursement timelines can materially change the strategic value of an early regulatory approval.